<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4976">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02054702</url>
  </required_header>
  <id_info>
    <org_study_id>331-13-008</org_study_id>
    <nct_id>NCT02054702</nct_id>
  </id_info>
  <brief_title>Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia</brief_title>
  <official_title>Protocol 331-13-008: An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore changes in efficacy, cognitive functioning, and
      safety of flexibly-dosed brexpiprazole monotherapy in subjects with acute schizophrenia
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The change from baseline to Week 6 in PANSS Total Score</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive test battery composite score change from baseline to Week 6 change from baseline to Week 6 in cognitive test battery composite score change from baseline to Week 6 in cognitive test battery CGI-S score change from baseline to Week 6</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I score at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SLOF Total Score change from baseline to Week 6</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIS-11 total score change from baseline to Week 6</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Brexpiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole</intervention_name>
    <description>Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally</description>
    <arm_group_label>Brexpiprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Up to 20 mg/day, once daily dose, tablets, orally</description>
    <arm_group_label>Aripiprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years of age, inclusive, at the time of informed consent with a diagnosis of
             schizophrenia as defined by the Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by the Mini
             International Neuropsychiatric Interview (M.I.N.I) for Schizophrenia and Phychotic
             Disorders Studies

          -  Would benefit from hospitalization or continued hospitalization for treatment of a
             current acute relapse of schizophrenia at trial entry

          -  Are experiencing an acute exacerbation of psychotic symptoms and marked deterioration
             of usual function as demonstrated by all of the following:

          -  Positive and Negative Syndrome Scale (PANSS) Total Score of ≥ 80

          -  Score of ≥ 4 on two or more of the following PANSS items at screening: hallucinatory
             behavior, unusual thought content, conceptual disorganization, or suspiciousness

          -  Clinical Global Impression - Severity of Illness Scale (CGI-S) score ≥ 4 (moderately
             ill)

        Exclusion Criteria:

          -  Are presenting with a first episode of schizophrenia based on the clinical judgment
             of the investigator

          -  Have been hospitalized &gt; 21 days for the current acute episode at the time of the
             baseline visit

          -  Have a current DSM-IV-TR Axis I diagnosis other than schizophrenia, including, but
             not limited to, schizoaffective disorder, major depressive disorder (MDD), bipolar
             disorder, post-traumatic stress disorder, anxiety disorders, delirium, dementia,
             amnestic, or other cognitive disorders; also borderline, paranoid, histrionic,
             schizotypal, schizoid, antisocial personality disorders or mental retardation.

          -  Improvement of ≥ 20% in total PANSS score between the screening and baseline
             assessments.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuko Hamatake</last_name>
    <role>Study Director</role>
    <affiliation>Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd Japan (OPCJ)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brexpiprazole.Program@quintiles.com</last_name>
  </overall_contact>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 2, 2014</lastchanged_date>
  <firstreceived_date>February 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Psychotic Disorders</keyword>
  <keyword>Antipsychotic</keyword>
  <keyword>Cognitive testing</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
